When Sweetness Brings Down Cancer
When it comes to old age, people are usually worried of conditions like high blood pressure, diabetes, heart problems and cancer. Usually, these conditions also spell out some of the primary causes of death worldwide, with cancer most likely at the top. There have been many attempts at research to figure out a cure for cancer but they have not been totally successful. Most of the time, we would just be concerned with treatments that can impede the growth of cancer cells.
Despite the kind of threat that cancer poses, it has been noted that rates of cancer death and the number of new cancer cases have significantly decreased. This result, in the case of male cancer patients, can be attributed to a huge decrease in the number being diagnosed for lung and prostate cancer. These two kinds of cancer are the most prominent forms occurring among males. However, approximately only half of people who are diagnosed for lung cancer while it is still early live for at least five years after they are diagnosed. Chances are even much smaller at 3% for people who have lung cancer that has metastasized.
At a certain point, people who are diagnosed with cancer hope to simply just manage their cancer such that it will not metastasize. It is interesting to note, however, that Dr. Peter J. Mazzone of the Cleveland Clinic was working on a research having to do with the management of lung cancer patients who are diabetics. Well, at least, the concern of the research was with lung cancer patients who are exposed to metformin or any other similar diabetic drug.
Metformin is a drug commonly known to be used as a treatment for type 2 diabetes. It is very promising since it works for people who are pre-diabetics such that they will not progress into becoming full-blown diabetics. It also has the same blood sugar management effect for people who are quite advanced into their diabetic condition. Apparently, aside from simply managing blood sugar levels, researchers have associated the drug with a higher possibility of lung cancer to not metastasize.
The group of Dr. Mazzone looked into the records of 157 patients who have been diagnosed with diabetes and lung cancer. For these patients, they have been already exposed to metformin and have been diagnosed with diabetes before they were diagnosed for lung cancer. Although some patients were treated with drugs similar to metformin like TZDs (thiazolidinediones), this was taken into consideration. Having compared the records of these patients with those lung cancer patients who have never taken any of the above mentioned drugs, it has been concluded that those who were exposed to the diabetic drugs had a slimmer chance of having their cancer metastasize.
Dr. Mazzone even looks forward to how this drug may be used for studies in chemoprevention for cancer patients who are considered to be risky. This could even go as far as making metformin one of the standard drugs for the treatment of lung cancer.